{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:42:13Z","timestamp":1789461733303,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,3]]},"DOI":"10.7759\/cureus.61572","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T11:48:53Z","timestamp":1717415333000},"source":"Crossref","is-referenced-by-count":1,"title":["A Systematic Review and Meta-Analysis on the Role of Bempedoic Acid in Cardiovascular Outcomes for Patients With Statin Intolerance"],"prefix":"10.7759","author":[{"given":"Mohamed H","family":"Serour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musab","family":"Egaimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahid","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Cardiovascular Disease","author":"Olvera Lopez E","year":"2024","unstructured":"Olvera Lopez E, Ballard BD, Jan A. Cardiovascular Disease. StatPearls , Treasure Island, FL; 2024."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-018-5653-9","article-title":"Cardiovascular disease (CVD) and associated risk factors among older adults in six low-and middle-income countries: results from SAGE Wave 1","volume":"18","author":"Ruan Y","year":"2018","unstructured":"Ruan Y, Guo Y, Zheng Y, et al.. Cardiovascular disease (CVD) and associated risk factors among older adults in six low-and middle-income countries: results from SAGE Wave 1. BMC Public Health. 2018, 18:778. 10.1186\/s12889-018-5653-9","journal-title":"BMC Public Health"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner Z","year":"2011","unstructured":"Reiner Z, Catapano AL, De Backer G, et al.. ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011, 32:1769-818. 10.1093\/eurheartj\/ehr158","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-019-1171-8","article-title":"Mechanisms underlying direct actions of hyperlipidemia on myocardium: an updated review","volume":"19","author":"Yao YS","year":"2020","unstructured":"Yao YS, Li TD, Zeng ZH. Mechanisms underlying direct actions of hyperlipidemia on myocardium: an updated review. Lipids Health Dis. 2020, 19:23. 10.1186\/s12944-019-1171-8","journal-title":"Lipids Health Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnab037","article-title":"A modern approach to dyslipidemia","volume":"43","author":"Berberich AJ","year":"2022","unstructured":"Berberich AJ, Hegele RA. A modern approach to dyslipidemia. Endocr Rev. 2022, 43:611-53. 10.1210\/endrev\/bnab037","journal-title":"Endocr Rev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy SM","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al.. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019, 73:3168-209. 10.1016\/j.jacc.2018.11.002","journal-title":"J Am Coll Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Byty\u00e7i I","year":"2022","unstructured":"Byty\u00e7i I, Penson PE, Mikhailidis DP, et al.. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022, 43:3213-23. 10.1093\/eurheartj\/ehac015","journal-title":"Eur Heart J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv043","article-title":"European atherosclerosis society consensus panel. Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes ES","year":"2015","unstructured":"Stroes ES, Thompson PD, Corsini A, et al.. European atherosclerosis society consensus panel. Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management. Eur Heart J. 2015, 36:1012-22. 10.1093\/eurheartj\/ehv043","journal-title":"Eur Heart J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2016.01.003","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group Update (2016)","volume":"32","author":"Mancini GB","year":"2016","unstructured":"Mancini GB, Baker S, Bergeron J, et al.. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group Update (2016). Can J Cardiol. 2016, 32:S35-65. 10.1016\/j.cjca.2016.01.003","journal-title":"Can J Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen SE","year":"2023","unstructured":"Nissen SE, Lincoff AM, Brennan D, et al.. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023, 388:1353-64. 10.1056\/NEJMoa2215024","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1615053","article-title":"Muscle and statins: from toxicity to the nocebo effect","volume":"18","author":"Pedro-Botet J","year":"2019","unstructured":"Pedro-Botet J, Climent E, Benaiges D. Muscle and statins: from toxicity to the nocebo effect. Expert Opin Drug Saf. 2019, 18:573-9. 10.1080\/14740338.2019.1615053","journal-title":"Expert Opin Drug Saf"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"An assessment by the Statin Muscle Safety Task Force: 2014 update","volume":"8","author":"Rosenson RS","year":"2014","unstructured":"Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA, The National Lipid Association's Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014, 8:S58-71. 10.1016\/j.jacl.2014.03.004","journal-title":"J Clin Lipidol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5551\/jat.RV17030","article-title":"Diagnosis and management of statin intolerance","volume":"26","author":"Alonso R","year":"2019","unstructured":"Alonso R, Cuevas A, Cafferata A. Diagnosis and management of statin intolerance. J Atheroscler Thromb. 2019, 26:207-15. 10.5551\/jat.RV17030","journal-title":"J Atheroscler Thromb"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013189","article-title":"Cardiology patient page. Statin intolerance","volume":"131","author":"Fitchett DH","year":"2015","unstructured":"Fitchett DH, Hegele RA, Verma S. Cardiology patient page. Statin intolerance. Circulation. 2015, 131:e389-91. 10.1161\/CIRCULATIONAHA.114.013189","journal-title":"Circulation"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.016262","article-title":"Original Value: Efficacy and safety of bempedoic acid in patients with hypercholesterolemia: systematic review and meta-analysis of randomized controlled trials","volume":"9","author":"Di Minno A","year":"2020","unstructured":"Di Minno A, Lupoli R, Calcaterra I, et al.. Original Value: Efficacy and safety of bempedoic acid in patients with hypercholesterolemia: systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2020, 9:e016262. 10.1161\/JAHA.119.016262","journal-title":"J Am Heart Assoc"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01101-9","article-title":"Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis","volume":"19","author":"Wang X","year":"2020","unstructured":"Wang X, Zhang Y, Tan H, et al.. Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol. 2020, 19:128. 10.1186\/s12933-020-01101-9","journal-title":"Cardiovasc Diabetol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2022.03.020","article-title":"Long-term safety and efficacy of bempedoic acid in patients with atherosclerotic cardiovascular disease and\/or heterozygous familial hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study)","volume":"174","author":"Ballantyne CM","year":"2022","unstructured":"Ballantyne CM, Banach M, Bays HE, et al.. Long-term safety and efficacy of bempedoic acid in patients with atherosclerotic cardiovascular disease and\/or heterozygous familial hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study). Am J Cardiol. 2022, 174:1-11. 10.1016\/j.amjcard.2022.03.020","journal-title":"Am J Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2020.10.060","article-title":"Rationale and design of the CLEAR-outcomes trial: evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance","volume":"235","author":"Nicholls S","year":"2021","unstructured":"Nicholls S, Lincoff AM, Bays HE, et al.. Rationale and design of the CLEAR-outcomes trial: evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. Am Heart J. 2021, 235:104-12. 10.1016\/j.ahj.2020.10.060","journal-title":"Am Heart J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-022-00552-7","article-title":"Potential cardiovascular events avoided with bempedoic acid plus ezetimibe fixed-dose combination compared with ezetimibe alone in patients with atherosclerotic cardiovascular disease taking maximally tolerated statins","volume":"23","author":"McQueen RB","year":"2023","unstructured":"McQueen RB, Baum SJ, Louie MJ, et al.. Potential cardiovascular events avoided with bempedoic acid plus ezetimibe fixed-dose combination compared with ezetimibe alone in patients with atherosclerotic cardiovascular disease taking maximally tolerated statins. Am J Cardiovasc Drugs. 2023, 23:67-76. 10.1007\/s40256-022-00552-7","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-048893","article-title":"Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: a systematic review and meta-analysis","volume":"12","author":"Lin Y","year":"2022","unstructured":"Lin Y, Parco C, Karathanos A, et al.. Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: a systematic review and meta-analysis. BMJ Open. 2022, 12:e048893. 10.1136\/bmjopen-2021-048893","journal-title":"BMJ Open"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.9696","article-title":"Bempedoic Acid for primary prevention of cardiovascular events in statin-intolerant patients","volume":"330","author":"Nissen SE","year":"2023","unstructured":"Nissen SE, Menon V, Nicholls SJ, et al.. Bempedoic Acid for primary prevention of cardiovascular events in statin-intolerant patients. JAMA. 2023, 330:131-40. 10.1001\/jama.2023.9696","journal-title":"JAMA"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2020.08.013","article-title":"Bempedoic acid for high-risk patients with CVD as adjunct lipid-lowering therapy: a cost-effectiveness analysis","volume":"14","author":"Perera K","year":"2020","unstructured":"Perera K, Kam N, Ademi Z, Liew D, Zomer E. Bempedoic acid for high-risk patients with CVD as adjunct lipid-lowering therapy: a cost-effectiveness analysis. J Clin Lipidol. 2020, 14:772-83. 10.1016\/j.jacl.2020.08.013","journal-title":"J Clin Lipidol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s12170-022-00694-y","article-title":"New Strategies for lowering low density lipoprotein cholesterol for cardiovascular disease prevention","volume":"16","author":"Gaine SP","year":"2022","unstructured":"Gaine SP, Quispe R, Patel J, Michos ED. New Strategies for lowering low density lipoprotein cholesterol for cardiovascular disease prevention. Curr Cardiovasc Risk Rep. 2022, 16:69-78. 10.1007\/s12170-022-00694-y","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins JP","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al.. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011, 343:d5928. 10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients With hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs U","year":"2019","unstructured":"Laufs U, Banach M, Mancini GB, et al.. Efficacy and safety of bempedoic acid in patients With hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019, 8:e011662. 10.1161\/JAHA.118.011662","journal-title":"J Am Heart Assoc"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2020.12.023","article-title":"Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial","volume":"320","author":"Rubino J","year":"2021","unstructured":"Rubino J, MacDougall DE, Sterling LR, Hanselman JC, Nicholls SJ. Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial. Atherosclerosis. 2021, 320:122-128. 10.1016\/j.atherosclerosis.2020.12.023","journal-title":"Atherosclerosis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12062444","article-title":"Management of statin intolerant patients in the era of novel lipid lowering therapies: A critical approach in clinical practice","volume":"12","author":"Bosco G","year":"2023","unstructured":"Bosco G, Di Giacomo Barbagallo F, Spampinato S, et al.. Management of statin intolerant patients in the era of novel lipid lowering therapies: A critical approach in clinical practice. J Clin Med. 2023, 12:10.3390\/jcm12062444","journal-title":"J Clin Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.17925\/HI.2023.17.2.1","article-title":"Bempedoic acid: lipid lowering for cardiovascular disease prevention","volume":"17","author":"Albosta M","year":"2023","unstructured":"Albosta M, Grant JK, Michos ED. Bempedoic acid: lipid lowering for cardiovascular disease prevention. Heart Int. 2023, 17:27-34. 10.17925\/HI.2023.17.2.1","journal-title":"Heart Int"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/255349-a-systematic-review-and-meta-analysis-on-the-role-of-bempedoic-acid-in-cardiovascular-outcomes-for-patients-with-statin-intolerance","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T11:48:56Z","timestamp":1717415336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/255349-a-systematic-review-and-meta-analysis-on-the-role-of-bempedoic-acid-in-cardiovascular-outcomes-for-patients-with-statin-intolerance"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.61572","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,3]]}}}